Company intelligence / Profile preview

Elto Pharma

Ownership: Private
Development stage: Commercial

Overview

Eltoprazine, Elto Pharma’s lead program, has successfully completed proof-of-concept Phase 2 human clinical studies in adult ADHD, Alzheimer's aggression, and Parkinson's disease levodopa-induced dyskinesia (LID). It has over 680 subject exposure, well-established safety, showed promising efficacy in movement and cognitive disorders, and has orphan drug designation for PD-LID[1][2][4][7].

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Amarantus Bioscience HoldingsPsychoGenics

Beyond the preview

Go deeper on Elto Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elto Pharma.

Explore the full profile